| Chemical Information | |
| Antiviral agent ID | DrugRepV_5611 | |
| Antiviral agent name | Mycophenolic Acid |  |
| IUPAC Name | (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid |  |
| SMILES (canonical) | CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)O)OC | |
| SMILES (isomeric) | CC1=C(C(=C(C2=C1COC2=O)O)C/C=C(\C)/CCC(=O)O)OC | |
| Molecular Formula | C17H20O6 | |
| Molecular Weight (g/mol) | 320.34 | |
| InChl | InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+ | |
| Common Name | Mycophenolic acid | |
| Synonyms | (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid | Acide mycophenolique | Acido micofenolico | Acidum mycophenolicum | Micofenolico acido | Mycophenolate | Mycophenolsäure | |
| Structural Information | |
 |
|
| Clinical Information | |
|
Category | Antineoplastic and Immunomodulating Agents
| |
|
Primary Indication (Clinical trial phases) | Approved
|  |
| Biological Information | |
|
Primary Indication (Disease Category) | Non Infectious Disease
| |
|
Primary Indication (Disease) | Organ rejection (immunosuppressants)
| |
|
Secondary Indication | Dengue virus (DENV) NA New Guinea C |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | Jeg-3
| |
|
Secondary Indication (Mode of viral infection) | Adsorption
| |
|
Secondary Indication (Viral titer) | 2.25 MOI
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | Pre infection (1 hour)
| |
|
Secondary Indication (Duration of drug delivery) | 24 hours
| |
|
Secondary Indication (Drug concentration) | 2 μM
| |
|
Secondary Indication (Cell based assay) | Immunoflourescence assay
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | Percentage Inhibition [ 80 % ] | |
|
Reference | Rausch K, Hackett BA, Weinbren NL, Reeder SM, Sadovsky Y, Hunter CA, Schultz DC, Coyne CB, Cherry S..Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus..Cell Rep. 2017 Jan 17;18(3):804-815. doi: 10.1016/j.celrep.2016.12.068. PMID:28099856
|  |
|
Comment | Nanchangmycin was identified as a potent inhibitor of Zika virus entry across all cell types tested, including physiologically relevant primary cells. Nanchangmycin also was active against other medically relevant viruses, including West Nile, dengue, and chikungunya viruses that use a similar route of entry.
| |